Search / 207 results found

  • Updated

EXTON, Pa., Sept. 16, 2021 /PRNewswire/ -- The June 2021 approval of Biogen/Eisai's Aduhelm fueled high initial expectations for the first-to-market disease-modifying therapy (DMT) for the treatment of Alzheimer's disease. Three months into the launch, Biogen claims that market access restrictions, clinical trial data relevance, and onboarding burden has toned down near-term expectations.

A tower climb in honor of the 20th anniversary of 9/11 will be held Sunday at 6:30 p.m. at the Indiana County Public Safety Academy, 529 Fire …